Cardiovascular phenotyping in mice

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 34-49

  Doevendans, Pieter A ^a   Daemen, Mat J ^a   De Muinck, Ebo D ^a   Smits, Jos F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Gene targeting; Hemodynamics; Morphology; Mouse; Phenotype

Indexed keywords

CARDIOVASCULAR DISEASE; DNA SYNTHESIS; ECHOCARDIOGRAPHY; GENETIC MANIPULATION; HEART; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE;

ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HEART; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; PHENOTYPE;

EID: 0032126378     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00073-X     Document Type: Review

References (125)

1. [1] Doevendans PA, Hunter JJ, Lembo G, Wollert KC, Chien KR. Strategies for studying cardiovascular diseases in transgenic mice and gene-targeted mice. In: Monastersky GM, Robl JM, editors. Strategies in transgenic animal science. Washington: American Society For Microbiology, 1995:107-144.
2. [2] Kubalak S, Doevendans PA, Rockman H, et al. Molecular analysis of cardiac muscle diseases based on mouse genetics. In: Adolph KW, editor. Human molecular genetics. Orlando: Academic Press, 1996:470-487.
3. [3] Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vitro development of blastocyst-derive embryonic stem cell lines: formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 1985;87:27-45.
4. [4] Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987;51:501-512.
5. [5] Chien KR. Cardiac muscle diseases in genetically engineered mice: evolution of molecular physiology. Am J Physiol 1995;269:H755-766.
6. [6] Rockman HA, Ono S, Ross RS, et al. Molecular and physiological alterations in murine ventricular dysfunction. Proc Natl Acad Sci USA 1994;91:2694-2698.
7. [7] Grupp IL, Subramaniam A, Hewett TE, Robbins J, Grupp G. Comparison of normal, hypodynamic, and hyperdynamic mouse hearts using isolated work-performing heart preparations. Am J Physiol 1993;265:H1401-1410.
8. [8] Webb S, Brown NA, Anderson RH. The structure of the mouse heart in late fetal stages. Anat Embryol Berl 1996;194:37-47.
9. [9] Meijler FL. Atrioventricular conduction versus heart size size form mouse to whale. J Am Coll Cardiol 1985;5:363-365.
10. [10] Lev M, Thaemert J. The conduction system of the mouse heart. Acta Anat 1973;85:342-352.
11. [11] McLean M, Prothero J. Determination of relative fiber orientation in heart muscle: methodological problems. Anat Rec 1992;232:459-465.
12. [12] Epstein ND, Cohn GM, Cyran F, Fananapazir L. Differences in clinical expression of hypertrophic cardiomyopathy associated with two distinct mutations in the beta-myosin heavy chain gene. A 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation 1992;86:345-352.
13. [13] Geisterfer Lowrance AA, Christe M, Conner DA, et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996;272:731-734.
14. [14] Gottshall KR, Hunter JJ, Tanaka N, et al. Ras-dependent pathways induce obstructive hypertrophy in echo-selected transgenic mice. Proc Natl Acad Sci USA 1997;94:4710-4715.
15. [15] Thuroff J, Hort W, Lichti H. Diameter of coronary arteries in 36 species of mammalian from mouse to giraffe. Basic Res Cardiol 1984;79:199-206.
16. [16] Leung WH, Stadius ML, Alderman EL. Determinants of normal coronary artery dimensions in humans. Circulation 1991;84:2294-2306.
17. [17] Michael LH, Entman ML, Hartley CJ, et al. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995;269:H2147-2154.
18. [18] Daemen MJ, Muinck E, Lutgens E, Smits JF. Chronic myocardial infarction in mice: structural and functional consequences. Circulation 1997;96:S102.
19. [19] Reiss K, Cheng W, Ferber A, et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA 1996;93:8630-8635.
20. [20] Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci USA 1997;94:6391-6396.
21. [21] Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-747.
22. [22] Milano CA, Dolber PC, Rockman HA, et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 1994;91:10109-10113.
23. [23] Barbee RW, Perry BD, Re RN, Murgo JP. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. Am J Physiol 1992;263:R728-733.
24. [24] Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte, DN.A. synthesis and binucleation during murine development. Am J Physiol 1996;271:H2183-2189.
25. [25] Koss KL, Ponniah S, Jones WK, Grupp IL, Kranias EG. Differential phospholamban gene expression in murine cardiac compartments. Molecular and physiological analyses. Circ Res 1995;77:342-353.
26. [26] Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 1995;147:29-34.
27. [27] Przylenk K, Groom AC. Microvascular evidence for a transition zone around a chronic myocardial infarct in the rat. Can J Physiol Pharmacol 1983;61:1516-1522.
28. [28] Olivetti G, Lagstra C, Quanini F, et al. Capilliary growth in anemia-induced ventricular wall remodeling in the rat heart. Circ Res 1989;65:1182-1192.
29. [29] Blank S, Chen V, Hamilton N, Salerno T, Ianuzzo C. Biochemical characteristics of mammalian myocardia. J Mol Cell Cardiol 1989;21:367-373.
30. [30] Earth E, Stammler G, Speiser B, Schaper J. Ultrastructural quantitation of mitochondria and myofilaments in cardiac muscle from 10 different animal species including man. J Mol Cell Cardiol 1992;24:669-681.
31. [31] Sheuer J, Bahn AK. Cardiac contractile proteins: adenosine triphosphatase activity and physiological function. Circ Res 1979;45:1-12.
32. [32] Soonpaa MH, Field LJ. Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice. Am J Physiol 1994;266:H1439-445.
33. [33] Soonpaa MH, Koh GY, Pajak L, et al. Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. J Clin Invest 1997;99:2644-2654.
34. [34] Hamet P, Richard L, Dam TV, et al. Apoptosis in target organs of hypertension. Hypertension 1995;26:642-648.
35. [35] Huber SA. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab Invest 1997;76:691-701.
36. [36] Bialik S, Geenen DL, Sasson I, et al. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest 1997;100:1363-1372.
37. [37] MacLellan WR, Schneider MD. Death by design. Programmed cell death in cardiovascular biology and disease. Circ Res 1997;81:137-144.
38. [38] Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L. Apoptosis in human myocardial infarction. Circulation 1997;95:320-323.
39. [39] Watanabe Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-1279.
40. [40] French LE, Tschopp J. Constitutive Fas ligand expression in several non-lymphoid mouse tissues: implications for immune-protection and cell turnover. Behring Inst Mitt 1996:156-160.
41. [41] Goldbarg A, Hellerstein H, Bruell J, Daroczy A. Electrocardiogram of the normal mouse, Mus musculus: general considerations and and genetic aspects. Cardiovasc Res 1968;2:93-99.
42. [42] Berul CI, Aronovitz MJ, Wang PJ, Mendelsohn ME. In vivo cardiac electrophysiology studies in the mouse. Circulation 1996;94:2641-2648.
43. [43] Berul CI, Christe ME, Aronovitz MJ, Seidman CE, Seidman JG, Mendelsohn ME. Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. J Clin Invest 1997;99:570-576.
44. [44] Binah O, Arieli R, Beck R, Rosen MR, Palti Y. Ventricular electrophysiological properties: is interspecies variability related to thyroid state?. Am J Physiol 1987;252:H1265-1274.
45. [45] Drouin E, Charpentier F, Gauthier C, Laurent K, Le Marec H. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. J Am Coll Cardiol 1995;26:185-192.
46. [46] Field L. Atrial natriuretic factor SV40 T-antigen transgenes produce tumors and cardiac arrhtythmias in mice. Science 1988;239:1029-1033.
47. [47] Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. New Engl J Med 1997;336:775-785.
48. [48] Ackerman MJ, Clapham DE. Ion channels - basic science and clinical disease [see comments]. New Engl J Med 1997;336:1575-1586.
49. [49] Folco E, Mathur R, Mori Y, Buckett P, Koren G. A cellular model for long QT syndrome. Trapping of heteromultimeric complexes consisting of truncated Kv1.1 potassium channel polypeptides and native Kv1.4 and Kv1.5 channels in the endoplasmic reticulum. J Biol Chem 1997;272:26505-26510.
50. [50] Jeron A, Mitchel G, Folco E, London B, Koren M. Characterization of a transgenic mouse with a long-QT-phenotype. Eur Heart J 1997;18:598A.
51. [51] Chevalier B, Medigue C, Baillard C, Swynghedauw B. Effect of the knockout of the IsK gene on the ventricular repolarisation in conscious mice. Eur Heart J 1997;18:599A.
52. [52] Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996;384:80-83.
53. [53] Capasso J, Robinson T, Anversa P. Alterations in collagen cross-linking impair myocardial contractility in the mouse heart. Circ Res 1989;65:1657-1664.
54. [54] Stemmer R, Akera T. Concealed positive force-frequency relationships in rat and mouse cardiac muscle revealed by ryanodine. Am J Physiol 1986;251:H1106-1110.
55. [55] Schwinger RH, Bohm M, Schmidt U, et al. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with non-failing hearts. Circulation 1995;92:3220-3228.
56. [56] Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-784.
57. [57] Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 1994;75:401-409.
58. [58] Luo W, Wolska BM, Grupp IL, et al. Phospholamban gene dosage effects in the mammalian heart. Circ Res 1996;78:839-847.
59. [59] Chen EP, Bittner HB, Davis RD, Folz RJ, Van Trigt P. Extracellular superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts. Circulation 1996;94:II412-II417.
60. [60] Kohmoto O, Ikenouchi H, Hirata Y, Momomura S, Serizawa T, Barry WH. Variable effects of endothelin-1 on [Ca2+]i transients, pHi, and contraction in ventricular myocytes. Am J Physiol 1993;265:H793-800.
61. [61] Kadambi VJ, Ponniah S, Harrer JM, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996;97:533-539.
62. [62] Barbee RW, Perry BD, Re RN, Murgo JP, Field LJ. Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ Res 1994;74:747-751.
63. [63] Wang P, Ba ZF, Burkhardt J, Chaudry IH. Trauma-hemorrhage and resuscitation in the mouse: effects on cardiac output and organ blood flow. Am J Physiol 1993;264:H1166-73.
64. [64] Rudolph AM, Heymann MA. The circulation of the fetus in utero. Methods for studying distribution of blood flow, cardiac output and organ blood flow. Circ Res 1967;21:163-184.
65. [65] Wetterlin S, Petterson C. Determination of cardiac output in the mouse. Res Exp Med (Berlin) 1979;174:143-151.
66. [66] Dawson TH. Engineering design of the cardiovascular system in mammals. Prentice Hall: Englewood Cliffs NY, 1991.
67. [67] Smits JF, Janssen BJ, Daemen MJ, Debets JJ. Role of AT1-and AT2-receptors in the vasoconstrictor response of angiotensin II in conscious mice. Hypertension 1997;30:1002.
68. [68] Lorenz JN, Robbins J. Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse. Am J Physiol 1997;272:H1137-1146.
69. [69] Koch WJ, Rockman HA, Samama P, et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 1995;268:1350-1353.
70. [70] Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science 1994;264:582-586.
71. [71] Lembo G, Rockman HA, Hunter JJ, et al. Elevated blood pressure and enhanced myocardial contractility in mice with severe IGF-1 deficiency. J Clin Invest 1996;98:2648-2655.
72. [72] Hoit B, Walsh R. In vivo echocardiographic assessment of left ventricular function in transgenic and gene-targeted mice. Trends Cardiovasc Med 1997;7:129-134.
73. [73] Taffet GE, Hartley CJ, Wen X, Pham T, Michael LH, Entman ML. Noninvasive indexes of cardiac systolic and diastolic function in hyperthyroid and senescent mouse. Am J Physiol 1996;270:H2204-2209.
74. [74] Tanaka N, Dalton N, Mao L, et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 1996;94:1109-1117.
75. [75] Hoit B, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular in gene-targeted mice with phospholamban deficiency. Circ Res 1995;77:632-637.
76. [76] Hoit BD, Khan ZU, Pawloski Dahm CM, Walsh RA. In vivo determination of left ventricular wall stress-shortening relationship in normal mice. Am J Physiol 1997;272:H1047-1052.
77. [77] Arts T, Bovendeerd PH, Prinzen FW, Reneman R. Relation between left ventricular cavity pressure and volume systolic fiber stress and strain in the wall. Biophys J 1991;59:93-102.
78. [78] Gui YH, Linask KK, Khowsathit P, Huhta JC. Doppler echocardiography of normal and abnormal embryonic mouse heart. Pediatr Res 1996;40:633-642.
79. [79] Keller BB, MacLennan MJ, Tinney JP, Yoshigi M. In vivo assessment of embryonic cardiovascular dimensions and function in day-10.5 to -14.5 mouse embryos. Circ Res 1996;79:247-255.
80. [80] Dyson E, Sucov HM, Kubalak SW, et al. Atrial-like phenotype is associated with embryonic ventricular failure in retinoid X receptor alpha - / - mice. Proc Natl Acad Sci USA 1995;92:7386-7390.
81. [81] Schlager G. Systolic blood pressure in 8 inbred strains of mice. Nature 1966;212:519-520.
82. [82] Krege JH, Hodgkin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 1995;95:1111-1115.
83. [83] Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990;16301:301-307.
84. [84] Cocchetto D, Bjornsson T. Methods for vascular access and collection of body fluids from the laboratory rat. Pharmaceut Sci 1983;72:465-492.
85. [85] Kramer K, van Acker SA, Voss HP, Grimbergen JA, van der Vijgh WJ, Bast A. Use of telemetry to record electrocardiogram and heart rate in freely moving mice. J Pharmacol Toxicol Methods 1993;30:209-215.
86. [86] Desai K, Sato R, Schauble E, Barsh G, Kobilka B, Bernstein D. Cardiovascular indexes in the mouse at rest and with excercise: new tools to study models of cardiac disease. Am J Physiol 1997;272:H1053-H1061.
87. [87] Handy R, Wallace P, Moore P. Inhibition of nitric oxide synthase by isothioureas: cardiovascular and antinociceptive effects. Pharmacol Biochem and Behav 1996;55:179-184.
88. [88] Dorn GW, Robbins J, Ball N, Walsh RA. Myosin heavy chain regulation and myocyte contractile depression after LV hypertrophy in aortic-banded mice. Am J Physiol 1994;267:H400-405.
89. [89] Hocher B, Thone Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-1389.
90. [90] Janssen B, Leenders P, Smits J. Short-term and long-term blood pressure variability in mice. Effects of L-NAME, metoprolol and atropine on spectral components of blood pressure. Hypertension 1997;30:1000.
91. [91] Zee RY, Lou YK, Griffiths LR, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992;184:9-15.
92. [92] Cambien F, Costerousse O, Tiret L, et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994;90:669-676.
93. [93] Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy [see comments]. New Engl J Med 1994;330:1634-1638.
94. [94] Dessi Fulgheri P, Catalini R, Sarzani R, et al. Angiotensin converting enzyme gene polymorphism and carotid atherosclerosis in a low-risk population. J Hypertens 1995;13:1593-1596.
95. [95] Ohkubo H, Kawakami H, Kakehi Y, et al. Generation of transgenic mice with elevated blood pressure by introduction of the rat renin and angiotensinogen genes. Proc Natl Acad Sci USA 1990;87:5153-5157.
96. [96] Sharp MG, Fettes D, Brooker G, et al. Targeted inactivation of the Ren-2 gene in mice. Hypertension 1996;28:1126-1131.
97. [97] Tanimoto K, Sugiyama F, Goto Y, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994;269:31334-31337.
98. [98] Davisson RL, Kim HS, Krege JH, Lager DJ, Smithies O, Sigmund CD. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J Clin Invest 1997;99:1258-1264.
99. [99] Esther Jr. CR, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996;74:953-965.
100. [100] Krege JH, John SW, Langenbach LL, et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995;375:146-148.
101. [101] Tian B, Meng Q, Chen Y, Krege J, Smithies O, Oparil S. Blood pressure and cardiovascular homeostasis in mice having reduced or absent angiotensin-converting enzyme gene function. Hypertension 1997;30:128-133.
102. [102] Ichiki T, Labosky PA, Shiota C, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995;377:748-750.
103. [103] Ito M, Oliverio MI, Mannon PJ, et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 1995;92:3521-3525.
104. [104] Chen X, Li W, Yoshida H, et al. Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 1997;272:F299-304.
105. [105] Fewell JG, Osinska H, Klevitsky R, et al. A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. Am J Physiol 1997;273:H1595-1605.
106. [106] Kaplan ML, Cheslow Y, Vikstrom K, et al. Cardiac adaptations to chronic exercise in mice. Am J Physiol 1994;267:H1167-1173.
107. [107] Buttrick PM, Kaplan M, Leinwand LA, Scheuer J. Alterations in gene expression in the rat heart after chronic pathological and physiological loads. J Mol Cell Cardiol 1994;26:61-67.
108. [108] Bank N, Aynedjian HS, Qiu JH, et al. Renal nitric oxide synthases in transgenic sickle cell mice. Kidney Int 1996;50:184-189.
109. [109] Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994;368:703-710.
110. [110] Ogura A, Asano T, Suzuki O, et al. Hereditary nephrotic syndrome with progression to renal failure in a mouse model (ICGN strain): clinical study. Nephron 1994;68:239-244.
111. 1A receptor-deficient mice. Am J Physiol 1997;273:F315-320.
112. [112] Rockman HA, Ross RS, Harris AN, et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991;88:8277-8281.
113. [113] Lembo G, Hunter JJ, Chien KR. Signaling pathways for cardiac growth and hypertrophy. Recent advances and prospects for growth factor therapy. Ann New York Acad Sci 1995;752:115-127.
114. [114] Rockman HA, Wachhorst SP, Mao L, Ross JJ. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;266:H2468-2475.
115. [115] Wiesel P, Mazzolai L, Nussberger J, Pedrazzini T. Two-kidney, one clip and one-kidney, one clip hypertension in mice. Hypertension 1997;29:1025-1030.
116. [116] de Simone G, Devereux RB, Camargo MJ, Wallerson DC, Laragh JH. Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993;264:H2103-2110.
117. [117] Corbier A, Lecaque D, Secchi J, Depouez B, Hamon G. Effects of 4 weeks of treatment with trandolapril on renal hypertension and cardiac and vascular hypertrophy in the rat. J Cardiovasc Pharmacol 1994;23(Suppl 4):S26-S29.
118. [118] Smits JF, Daemen MJ. Insights from animal models of myocardial infarction: do ACE inhibitors limit the structural response?. Br Heart J 1994;72:S61-64.
119. [119] Hongo M, Ryoke T, Ross JJ. Animal models of heart failure: recent developments and perspectives. Trends Cardiovasc Med 1997;7:161-167.
120. [120] Smits JF, van Krimpen C, Schoemaker RG, Cleutjens JP, Daemen MJ. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol 1992;20:772-778.
121. [121] Fishman GI. Conditional transgenics. Trends Cardiovasc Med 1995;5:211-217.
122. [122] Fishman GI, Kaplan ML, Buttrick PM. Tetracycline-regulated cardiac gene expression in vivo. J Clin Invest 1994;93:1864-1868.
123. [123] Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 1994;265:103-106.
124. [124] Agah R, Frenkel PA, French BA, Michael LH, Overbeek PA, Schneider MD. Gene recombination in postmitotic cells. Targeted expression of Cre recombinase provokes cardiac-restricted site specific gene rearrangement in ventricular muscle in vivo. J Clin Invest 1997;100:169-179.
125. [125] St-Onge L, Furth PA, Gruss P. Temporal control of the Cre recombinase in trnasgenic mice by a tetracycline responsive promoter. Nucleic Acids Res 1997;24:3875-3877.